Examining Pharmaceutical Patent Practices & Their Impact on Drug Prices

Live Webcast Available at 9:00 a.m. ET

No login information is required to view this live webcast.

Submit a Question

To submit questions during the webcast, tweet using #BPClive or email [email protected].

Program
Fireside chat:
Drew Hirshfeld, J.D. | Commissioner, United States Patent and Trademark Office

Markus Meier, J.D. | Assistant Director for Healthcare, Federal Trade Commission

Dr. Avik Roy | President, Foundation for Research on Equal Opportunity

Academic Panel discussion featuring:
Michael Carrier, J.D. | Distinguished Professor, Rutgers Law School

Robin Feldman, J.D. | Arthur J. Goldberg Distinguished Professor of Law and Director of the Center for Innovation, University of California Hastings

Arti Rai, J.D. | Elvin R. Latty Professor of Law and Faculty Director, The Center for Innovation Policy, Duke University Law School

Melissa Wasserman, J.D. | Charles Tilford McCormick Professor of Law, University of Texas at Austin School of Law

Moderated by:

Dr. Anand Parekh | Chief Medical Advisor, Bipartisan Policy Center

Stakeholder Panel discussion featuring:
Tahir Amin, L.L.B. | Co-founder and Executive Director, I-MAK

Melissa Brand, J.D. | Associate Counsel, Biotechnology Innovation Organization

Karen Hessler, J.D. | Assistant General Counsel, Association for Accessible Medicines

Moderated by:

Charles Duan, J.D. | Director of Technology and Innovation, R Street

While pharmaceutical patents and market exclusivity can incentivize innovation in the United States, various patent practices can also impact the affordability of brand drugs and biologics, especially for debilitating conditions such as rheumatoid arthritis, cancer, and diabetes.  Please join us on Tuesday,

December 10, as BPC hosts a panel of experts to discuss the tactics used to delay competition through the patent system and the possible policy solutions to address this important issue.